ARCpoint Inc
ARC
Minas Metals Ltd
MINA
Quri-Mayu Developments Ltd
QURI
KGL Resources Ltd
KGL.H
Alerio Gold Corp
ALE
CA Stock MarketDetailed Quotes
XTCY Xtacy Therapeutics Corp
- 0.030
- 0.0000.00%
15min DelayMarket Closed Nov 4 09:38 ET
1.74MMarket Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.030Pre Close0.00Turnover0.09552wk High0.00%Turnover Ratio58.16MShares0.02052wk Low--EPS TTM1.57MFloat Cap0.115Historical HighLossP/E (Static)52.35MShs Float0.020Historical Low-0.01EPS LYR0.00%Amplitude--Dividend TTM-5.00P/B1Lot Size--Div YieldTTM
Xtacy Therapeutics Corp Key Stats
Quarterly+Annual
YOY
| (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -113.14%-77.44K | 115.83%77.44K | 0 | 81.07%-80.7K | 30.69%-216.7K | 589.29K | -435.92%-489.29K | 260.99%36K | -333.02%-426.3K | -4,837.37%-312.63K |
| Net income from continuing operations | 65.95%-123.42K | 74.64%-65.73K | -68.69%-265.84K | 62.01%-519.94K | 130.87%259.31K | ---362.52K | -146.29%-259.13K | 62.79%-157.6K | 61.81%-1.37M | 65.94%-839.98K |
| Operating gains losses | ---- | ---- | ---- | -103.85%-23.29K | ---- | ---- | ---- | ---- | 96.18%-11.43K | ---- |
| Other non cashItems | -101.99%-11.62K | ---77.6K | --268.24K | -233.24%-400.88K | -1,491.98%-1.43M | --584.54K | ---- | ---- | 18.16%300.87K | 38.34%-90.1K |
| Change In working capital | 265.85%135.04K | 162.22%143.33K | -101.24%-2.4K | 32.22%863.41K | 56.09%981.6K | ---81.42K | -461.64%-230.37K | 589.19%193.6K | 30.50%652.99K | 74.08%628.87K |
| -Change in prepaid assets | ---- | ---- | ---- | 193.70%279.08K | ---- | ---- | ---- | ---- | ---297.83K | ---- |
| -Change in payables and accrued expense | ---- | ---- | ---- | -38.54%584.33K | ---- | ---- | ---- | ---- | 90.01%950.82K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | --0 | --0 | --0 | 81.07%-80.7K | 30.69%-216.7K | --140.6K | 55.53%-40.6K | 260.99%36K | -333.02%-426.3K | -4,837.37%-312.63K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Cash from discontinued investing activities | ||||||||||
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 0 | 0 | -79.86%80.7K | -27.94%216.7K | -140.6K | 424.75%40.6K | -132.01%-36K | 233.68%400.67K | 300.72K |
| Net issuance payments of debt | --0 | ---- | ---- | 527.86%29.02K | --29.02K | ---4.6K | ---- | ---- | -109.04%-6.78K | ---- |
| Net common stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --407.45K | ---- |
| Net other financing activities | ---- | ---- | ---- | --51.68K | --187.68K | ---- | ---- | -132.01%-36K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | --0 | --0 | -79.86%80.7K | -27.94%216.7K | ---140.6K | 424.75%40.6K | -132.01%-36K | 233.68%400.67K | --300.72K |
| Net cash flow | ||||||||||
| Beginning cash position | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | 540.86%25.63K | -62.71%11.92K |
| Current changes in cash | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -218.49%-25.63K | -88.20%-11.92K |
| End cash Position | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Free cash from | --0 | --0 | --0 | 81.07%-80.7K | 30.69%-216.7K | --140.6K | 55.53%-40.6K | 260.99%36K | -333.02%-426.3K | -4,837.37%-312.63K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.